Regeneron Pharmaceuticals, Inc.
Case Overview
49 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 03/10/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Regeneron Pharmaceuticals, Inc. |
Court: | Court: Southern District of New York |
Case Number: | Case Number: 1:25cv00145 |
Class Period: | Class Period: 11/02/2023 - 10/30/2024 |
Ticker: | Ticker: REGN |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ:REGN) securities during the period of November 2, 2023, to October 30, 2024, inclusive (“the Class Period”). Investors have until March 10, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others. One of Regeneron’s lead products is Elyea, an injection to treat age-related macular degeneration by inhibiting anti-vascular endothelial growth factor (“anti-VEGF”). Regeneron also offers Elyea HD, a high dose version of Eylea. The Company is “substantially dependent on the success of Elyea [and] Elyea HD.” Sales of the Company’s products, including Eylea and Eylea HD, are, in turn, largely dependent on the availability and extent of reimbursement from third-party payors, including pro-grams such as Medicare and Medicaid. The reimbursement rate of each claim submitted for Eylea and Eylea HD is based on the Average Sales Price (“ASP”) reported by Regeneron. In reporting ASP, companies like Regeneron are required to include all price concessions, such as volume discounts, chargebacks, and rebates, as part of their calculation, meaning companies must report net price received after accounting for these concessions.
On April 10, 2024, the U.S. Department of Justice (“DOJ”) announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to re-port millions of dollars in discounts provided to drug distributors in the form of reimbursed credit card fees. As a result, the DOJ alleges that Elyea’s ASP was inflated, which inappropriately in-creased Medicare reimbursements. By reimbursing credit card fees, Regeneron subsidized the treatment costs, thereby gaining a competitive advantage over other anti-VEGF treatments. On this news, Regeneron shares declined by $31.50 per share, over two consecutive trading days, from $936.20 per share on April 10, 2024, to close at $904.70 on April 12, 2024.
Then, on October 31, 2024, before the market opened, Regeneron released its third quarter 2024 financial results, revealing lagging U.S. net sales for Elyea and Elyea HD. The Company reported sales had only increased 3% vs. the third quarter 2024, and quarterly sales of Elyea HD were only $392 million, missing consensus estimates of $415 million to $425 million. Regeneron also revealed that “net product sales of EYLEA in the third quarter of 2024 were adversely impacted by lower net selling price compared to the third quarter of 2023.” On this news, Regeneron shares declined by $84.59 per share, from $922.79 per share on October 30, 2024, to close at $838.20 on October 31, 2024.
The complaint alleges that defendants, throughout the Class Period, made materially false and/or misleading statements, as well as failed to disclose that: (1) that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card; (2) that these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) that, as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (4) that, because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron’s price concessions provided a competitive advantage; (5) that, as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; and (6) that, by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act.
Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others. One of Regeneron’s lead products is Elyea, an injection to treat age-related macular degeneration by inhibiting anti-vascular endothelial growth factor (“anti-VEGF”). Regeneron also offers Elyea HD, a high dose version of Eylea. The Company is “substantially dependent on the success of Elyea [and] Elyea HD.” Sales of the Company’s products, including Eylea and Eylea HD, are, in turn, largely dependent on the availability and extent of reimbursement from third-party payors, including pro-grams such as Medicare and Medicaid. The reimbursement rate of each claim submitted for Eylea and Eylea HD is based on the Average Sales Price (“ASP”) reported by Regeneron. In reporting ASP, companies like Regeneron are required to include all price concessions, such as volume discounts, chargebacks, and rebates, as part of their calculation, meaning companies must report net price received after accounting for these concessions.
On April 10, 2024, the U.S. Department of Justice (“DOJ”) announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to re-port millions of dollars in discounts provided to drug distributors in the form of reimbursed credit card fees. As a result, the DOJ alleges that Elyea’s ASP was inflated, which inappropriately in-creased Medicare reimbursements. By reimbursing credit card fees, Regeneron subsidized the treatment costs, thereby gaining a competitive advantage over other anti-VEGF treatments. On this news, Regeneron shares declined by $31.50 per share, over two consecutive trading days, from $936.20 per share on April 10, 2024, to close at $904.70 on April 12, 2024.
Then, on October 31, 2024, before the market opened, Regeneron released its third quarter 2024 financial results, revealing lagging U.S. net sales for Elyea and Elyea HD. The Company reported sales had only increased 3% vs. the third quarter 2024, and quarterly sales of Elyea HD were only $392 million, missing consensus estimates of $415 million to $425 million. Regeneron also revealed that “net product sales of EYLEA in the third quarter of 2024 were adversely impacted by lower net selling price compared to the third quarter of 2023.” On this news, Regeneron shares declined by $84.59 per share, from $922.79 per share on October 30, 2024, to close at $838.20 on October 31, 2024.
The complaint alleges that defendants, throughout the Class Period, made materially false and/or misleading statements, as well as failed to disclose that: (1) that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card; (2) that these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) that, as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (4) that, because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron’s price concessions provided a competitive advantage; (5) that, as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; and (6) that, by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act.